Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study
- 7 February 2019
- journal article
- research article
- Published by Elsevier in Respiratory Investigation
- Vol. 57 (4) , 345-353
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceutical K.K.
This publication has 13 references indexed in Scilit:
- Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug‐Resistant Tuberculosis: The Effect of Time‐Varying Weight and AlbuminCPT: Pharmacometrics & Systems Pharmacology, 2016
- Adverse Events Associated With the Treatment of Multidrug-Resistant TuberculosisAmerican Journal of Therapeutics, 2016
- Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosisEuropean Respiratory Journal, 2015
- Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis DrugAntimicrobial Agents and Chemotherapy, 2014
- Multidrug-Resistant Tuberculosis and Culture Conversion with BedaquilineNew England Journal of Medicine, 2014
- Bedaquiline: a review of human pharmacokinetics and drug-drug interactionsJournal of Antimicrobial Chemotherapy, 2014
- Bedaquiline – The first ATP synthase inhibitor against multi drug resistant tuberculosisJournal of Young Pharmacists, 2013
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug ResistanceAntimicrobial Agents and Chemotherapy, 2012
- The Diarylquinoline TMC207 for Multidrug-Resistant TuberculosisNew England Journal of Medicine, 2009
- A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosisScience, 2005